Crispr Therapeutics (NASDAQ:CRSP) had its price objective hoisted by Oppenheimer from $65.00 to $80.00 in a report issued on Monday, November 25th, The Fly reports. They currently have an outperform rating on the stock. Oppenheimer also issued estimates for Crispr Therapeutics’ FY2019 earnings at $0.59 EPS, Q1 2020 earnings at ($0.89) EPS, Q2 2020 earnings at ($0.97) EPS, Q3 2020 earnings at ($1.32) EPS, Q4 2020 earnings at ($1.42) EPS, FY2020 earnings at ($4.63) EPS, FY2021 earnings at ($4.47) EPS, FY2022 earnings at ($4.98) EPS and FY2023 earnings at ($2.03) EPS.
Several other equities analysts have also commented on the company. ValuEngine raised Crispr Therapeutics from a sell rating to a hold rating in a research report on Friday, November 1st. Canaccord Genuity boosted their price objective on shares of Crispr Therapeutics from $72.00 to $80.00 and gave the stock a positive rating in a research note on Wednesday, November 20th. Barclays upped their price objective on shares of Crispr Therapeutics from $59.00 to $62.00 and gave the stock an overweight rating in a report on Tuesday, July 30th. Wells Fargo & Co reissued a buy rating on shares of Crispr Therapeutics in a research report on Tuesday, November 19th. Finally, TheStreet upgraded Crispr Therapeutics from a d rating to a c rating in a research note on Monday, October 28th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and fourteen have given a buy rating to the company. The stock has an average rating of Buy and an average price target of $69.54.
Shares of CRSP opened at $65.36 on Monday. The company has a quick ratio of 8.32, a current ratio of 8.32 and a debt-to-equity ratio of 0.06. Crispr Therapeutics has a 1-year low of $22.22 and a 1-year high of $74.00. The firm’s 50-day moving average price is $58.93 and its 200-day moving average price is $48.44.
Crispr Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Monday, October 28th. The company reported $2.40 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.95) by $3.35. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. The business had revenue of $211.93 million for the quarter, compared to analysts’ expectations of $6.32 million. Sell-side analysts anticipate that Crispr Therapeutics will post 0.65 earnings per share for the current year.
In other Crispr Therapeutics news, Director Pablo J. Cagnoni sold 7,500 shares of Crispr Therapeutics stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $55.00, for a total value of $412,500.00. Following the completion of the sale, the director now owns 7,500 shares of the company’s stock, valued at approximately $412,500. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, President Rodger Novak sold 33,618 shares of the company’s stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total value of $2,353,260.00. Following the transaction, the president now directly owns 33,618 shares in the company, valued at $2,353,260. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 56,118 shares of company stock valued at $3,620,760. 21.40% of the stock is owned by company insiders.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Benjamin Edwards Inc. grew its stake in shares of Crispr Therapeutics by 96.4% in the second quarter. Benjamin Edwards Inc. now owns 546 shares of the company’s stock worth $26,000 after acquiring an additional 268 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Crispr Therapeutics by 13.6% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,870 shares of the company’s stock worth $118,000 after purchasing an additional 343 shares during the period. Traynor Capital Management Inc. grew its position in Crispr Therapeutics by 5.8% in the 3rd quarter. Traynor Capital Management Inc. now owns 6,845 shares of the company’s stock worth $280,000 after purchasing an additional 375 shares during the period. Commonwealth Equity Services LLC raised its stake in Crispr Therapeutics by 2.2% during the 3rd quarter. Commonwealth Equity Services LLC now owns 18,201 shares of the company’s stock valued at $746,000 after buying an additional 386 shares during the last quarter. Finally, D. E. Shaw & Co. Inc. raised its stake in Crispr Therapeutics by 7.1% during the 2nd quarter. D. E. Shaw & Co. Inc. now owns 7,019 shares of the company’s stock valued at $331,000 after buying an additional 467 shares during the last quarter. 49.82% of the stock is currently owned by hedge funds and other institutional investors.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Featured Story: Google Finance Portfolio Tips and Tricks
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.